{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:47:23Z","timestamp":1791478043974,"version":"4.3.4"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":1844,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T00:00:00Z","timestamp":1608595200000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Intravenous ferric carboxymaltose (FCM) has been shown to improve functional capacity and quality of life in iron deficient heart failure patients. However, FCM's effect on hospitalizations and mortality remains unclear as previous randomized controlled trials (RCTs) and their meta-analyses have been underpowered to detect significant differences. We sought to conduct an updated meta-analysis using recently published RCT data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Online databases were searched from inception until November 2020 for RCTs evaluating the effects of FCM on clinical outcomes in iron-deficient heart failure patients. Outcomes of interest included heart failure hospitalizations, all-cause mortality, and cardiovascular mortality. Meta-analysis was performed using a fixed-effect model and estimates were reported as odds ratios (ORs), hazard ratios, or rate ratios (RRs) along with corresponding 95% confidence intervals (CIs). A total of 1947 patients (n = 1062 in the FCM group; n = 885 in the placebo group) were included. FCM, compared with placebo, significantly reduced the risk of the composite endpoint of time to first heart failure hospitalization or cardiovascular death (hazard ratio = 0.76; 95% CI = 0.63\u20130.90; I2 = 55%). FCM also significantly reduced the risk of recurrent heart failure hospitalizations (RR = 0.68; 95% CI = 0.54\u20130.85; I2 = 71%) and recurrent cardiovascular hospitalizations (RR = 0.71; 95% CI = 0.59\u20130.86; I2 = 56%). However, FCM had no significant effect on the risk of all-cause (OR = 0.97; 95% CI = 0.73\u20131.28; I2 = 0%) or cardiovascular mortality (OR = 0.93; 95% CI = 0.69\u20131.27; I2 = 0%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Ferric carboxymaltose reduces heart failure hospitalizations and cardiovascular hospitalizations with no beneficial effect on all-cause and cardiovascular mortality in iron-deficient heart failure patients. These findings reinforce the role of FCM as a therapeutic option in heart failure patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.13146","type":"journal-article","created":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T18:48:53Z","timestamp":1608662933000},"page":"3392-3400","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Ferric Carboxymaltose for the Treatment of Iron-Deficient Heart Failure Patients: A Systematic Review and Meta-Analysis"],"prefix":"10.1093","volume":"7","author":[{"given":"Muhammad Shahzeb","family":"Khan","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Mississippi Medical Centre , Jackson, MS ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Shariq","family":"Usman","sequence":"additional","affiliation":[{"name":"Department of Medicine, DOW University of Health Sciences , Karachi ,","place":["Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"von Haehling","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Pneumology, University of G\u00f6ttingen Medical Center , G\u00f6ttingen ,","place":["Germany"]},{"name":"German Center for Cardiovascular Research (DZHK), partner site G\u00f6ttingen , G\u00f6ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfram","family":"Doehner","sequence":"additional","affiliation":[{"name":"BCRT\u2014Berlin Institute of Health Center for Regenerative Therapies, Charite, Universit\u00e4tsmedizin Berlin , Berlin ,","place":["Germany"]},{"name":"Department of Cardiology (Virchow Klinikum), Charit\u00e9- Universit\u00e4tsmedizin Berlin, German Centre for Cardiovascular Research (DZHK), Partner Site Berlin , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Stewart Coats","sequence":"additional","affiliation":[{"name":"Monash University","place":["Australia"]},{"name":"University of Warwick , Coventry ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,12,22]]},"reference":[{"key":"2026012115022966100_ehf213146-bib-0001","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.030099","article-title":"Anemia and iron deficiency in heart failure: current concepts and emerging therapies","volume":"138","author":"Anand","year":"2018","journal-title":"Circulation"},{"key":"2026012115022966100_ehf213146-bib-0002","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/ehf2.12333","article-title":"Iron deficiency in chronic heart failure: case-based practical guidance","volume":"5","author":"Lam","year":"2018","journal-title":"ESC Heart Fail"},{"key":"2026012115022966100_ehf213146-bib-0003","doi-asserted-by":"crossref","first-page":"173","DOI":"10.15420\/cfr.2019.9.2","article-title":"Why is iron deficiency recognised as an important comorbidity in heart failure?","volume":"5","author":"Ebner","year":"2019","journal-title":"Card Fail Rev"},{"key":"2026012115022966100_ehf213146-bib-0004","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"2026012115022966100_ehf213146-bib-0005","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","article-title":"Ferric carboxymaltose in patients with heart failure and iron deficiency","volume":"361","author":"Anker","year":"2009","journal-title":"N Engl J Med"},{"key":"2026012115022966100_ehf213146-bib-0006","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.amjmed.2019.02.018","article-title":"Iron supplementation improves cardiovascular outcomes in patients with heart failure","volume":"132","author":"Zhou","year":"2019","journal-title":"Am J Med"},{"key":"2026012115022966100_ehf213146-bib-0007","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1093\/eurjhf\/hft099","article-title":"Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial","volume":"15","author":"Filippatos","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2026012115022966100_ehf213146-bib-0008","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/eurheartj\/ehu385","article-title":"Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency","volume":"36","author":"Ponikowski","year":"2015","journal-title":"Eur Heart J"},{"key":"2026012115022966100_ehf213146-bib-0009","article-title":"Improving exercise capacity and quality of life using non-invasive heart failure treatments: evidence from clinical trials","author":"von Haehling","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012115022966100_ehf213146-bib-0010","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1161\/CIRCULATIONAHA.117.027497","article-title":"Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency","volume":"136","author":"van Veldhuisen","year":"2017","journal-title":"Circulation"},{"key":"2026012115022966100_ehf213146-bib-0011","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)32339-4","article-title":"Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre randomised, controlled, double-blind trial","author":"Ponikowski","year":"2020","journal-title":"Lancet"},{"key":"2026012115022966100_ehf213146-bib-0012","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"2026012115022966100_ehf213146-bib-0013","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/ejhf.823","article-title":"Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis","volume":"20","author":"Anker","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115022966100_ehf213146-bib-0014","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2026012115022966100_ehf213146-bib-0015","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"2026012115022966100_ehf213146-bib-0016","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/jrsm.12","article-title":"A basic introduction to fixed-effect and random-effects models for meta-analysis","volume":"1","author":"Borenstein","year":"2010","journal-title":"Res Synth Methods"},{"key":"2026012115022966100_ehf213146-bib-0017","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Sterne","year":"2019","edition":"2nd ed."},{"key":"2026012115022966100_ehf213146-bib-0018","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004873","article-title":"National burden of heart failure events in the United States, 2006 to 2014","volume":"11","author":"Jackson","year":"2018","journal-title":"Circ Heart Fail"},{"key":"2026012115022966100_ehf213146-bib-0019","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/ehf2.12021","article-title":"Improving care for patients with acute heart failure: before, during and after hospitalization","volume":"1","author":"Cowie","year":"2014","journal-title":"ESC Heart Fail"},{"key":"2026012115022966100_ehf213146-bib-0020","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1161\/CIRCULATIONAHA.117.032099","article-title":"Glucose-lowering therapies and heart failure in type 2 diabetes mellitus: mechanistic links, clinical data, and future directions","volume":"137","author":"Vijayakumar","year":"2018","journal-title":"Circulation"},{"key":"2026012115022966100_ehf213146-bib-0021","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.jchf.2020.05.011","article-title":"The maximally tolerated dose: the key context for interpreting subtarget medication dosing for heart failure","volume":"8","author":"Greene","year":"2020","journal-title":"JACC Heart Fail"},{"key":"2026012115022966100_ehf213146-bib-0022","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/j.jacc.2019.02.015","article-title":"Titration of medical therapy for heart failure with reduced ejection fraction","volume":"73","author":"Greene","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026012115022966100_ehf213146-bib-0023","doi-asserted-by":"crossref","first-page":"S138","DOI":"10.1016\/j.cardfail.2019.07.399","article-title":"Outcome of titrating guideline directed medical therapy in heart failure patients at 90-day post-hospital discharge","volume":"25","author":"Eivazi","year":"2019","journal-title":"J Card Fail"},{"key":"2026012115022966100_ehf213146-bib-0024","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1161\/CIRCOUTCOMES.110.959122","article-title":"Get with the guidelines program participation, process of care, and outcome for Medicare patients hospitalized with heart failure","volume":"5","author":"Heidenreich","year":"2012","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2026012115022966100_ehf213146-bib-0025","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/ehf2.12432","article-title":"Budget impact of intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency in France","volume":"6","author":"Bourguignon","year":"2019","journal-title":"ESC Heart Fail"},{"key":"2026012115022966100_ehf213146-bib-0026","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/ehf2.12179","article-title":"Budget impact of intravenous iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in Germany","volume":"4","author":"Theidel","year":"2017","journal-title":"ESC Heart Fail"},{"key":"2026012115022966100_ehf213146-bib-0027","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/ehf2.12400","article-title":"Differences between intravenous iron products: focus on treatment of iron deficiency in chronic heart failure patients","volume":"6","author":"Martin-Malo","year":"2019","journal-title":"ESC Heart Fail"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.13146","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.13146","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/7\/6\/3392\/65902272\/eschf_7_6_3392.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/7\/6\/3392\/65902272\/eschf_7_6_3392.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T20:02:37Z","timestamp":1769025757000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/7\/6\/3392\/8372452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,1]]},"references-count":27,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,12,22]]},"published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.13146","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12]]},"published":{"date-parts":[[2020,12,1]]},"assertion":[{"value":"2020-11-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}